|
|
Ngày nhập |
| 4879 |
Compatibility of Active Pharmaceutical Ingredients in Cleoderm: A Comprehensive Study for Enhanced Topical Dermatological Treatments. Int J Pharm Compound |
08/11/2024 |
| 4880 |
Stability of Allopurinol in Extemporaneously Compounded Oral Suspensions with Oral Mix and Oral Mix SF. Int J Pharm Compound |
08/11/2024 |
| 4867 |
Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 |
17/10/2024 |
| 4868 |
Etude de la stabilité physico-chimique de solutions de 5-fluorouracile diluées en poches polyoléfine a des concentrations comprises entre 9 et 15 mg/ml. CSH (SNPHPU) Congress sept 2024 |
17/10/2024 |
| 4865 |
Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. Dr REDDY laboratoire |
01/10/2024 |
| 4863 |
Physical Compatibility Between Intravenous Magnesium Sulfate and Potassium or Sodium Phosphate in a Pediatric Intensive Care Unit. Hosp Pharm |
25/09/2024 |
| 4855 |
Physical compatibility of colistin with analgesics during simulated Y-site administration. Am J Hosp Pharm |
04/09/2024 |
| 4857 |
Physicochemical and Microbiological Stability of Compounded Clonidine Hydrochloride Oral iquid Dosage Forms in PCCA Base, SuspendIt®. Int J Pharm Compound |
04/09/2024 |
| 4858 |
Physical Compatibility of Intravenous Ondansetron Hydrochloride and Nafcillin Sodium. Int J Pharm Compound |
04/09/2024 |
| 4859 |
Physicochemical and Microbiological Stability of Compounded Bethanechol Chloride Oral Suspensions in PCCA Base, SuspendIt® Int J Pharm Compound |
04/09/2024 |
| 4862 |
Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. Porton Biopharma Limited |
04/09/2024 |
| 4852 |
KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. Merck Sharp & Dohme B.V. |
25/08/2024 |
| 4849 |
Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers? Pharmaceuticals |
22/08/2024 |
| 4850 |
The Infusion of Piperacillin/Tazobactam with an Elastomeric Device: A Combined 24-H Stability Study and Drug Solution Flow Rate Analysis. Pharmaceuticals |
22/08/2024 |
| 4851 |
Long-term stability of esketamine in polypropylene syringes at 5 ± 3°C. EJHP |
22/08/2024 |
| 4846 |
Chemical Stability of Lorazepam Oral Solution Repackaged in Plastic Oral Syringes at Room and Refrigerated Temperature. Hosp Pharm |
03/07/2024 |
| 4843 |
Y-Site Compatibility Studies of Ketoprofen with Parenteral Nutrition Admixtures for Central and Peripheral Administration. Pharmaceutics |
30/06/2024 |
| 4842 |
Harmonising IV Oxycodone with Paediatric Perioperative Medications: A Compatibility Study Through Y-Type Connectors Drug Design Dev Ther |
28/06/2024 |
| 4835 |
Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental |
16/06/2024 |
| 4837 |
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol |
16/06/2024 |
| 4828 |
The Physical Compatibility of Glycopyrrolate and Rocuronium. Anesth Prog |
15/06/2024 |
| 4831 |
Frequently acquired drugs in neonatal intensive care and their physical compatibility. Acta Paediatr |
15/06/2024 |
| 4832 |
Co‑administration of drugs with parenteral nutrition in the neonatal intensive care unit—physical compatibility between three components. Eur J Pedia |
15/06/2024 |
| 4824 |
Physicochemical stability of pevonedistat at 50, 100 and 200 µg/mL diluted in 0.9% sodium chloride and at 10 mg/mL in partially used vials. EJHP |
03/06/2024 |
| 4825 |
Physicochemical and microbiological stability study of two new preservative-free methylprednisolone eye drops. Farm Hosp |
03/06/2024 |
| 4822 |
Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist |
08/05/2024 |
| 4821 |
AmBisome® Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies. Pharmaceutics |
28/04/2024 |
| 4820 |
Physicochemical and biological stability of diluted vedolizumab in intravenous infusion bags. EJHP |
17/04/2024 |
| 4819 |
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations. Int J Pharm |
09/04/2024 |
| 4818 |
Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 PAION UK Ltd |
04/04/2024 |
